

CORRIGENDUM: Phenotype-driven gene target definition in clinical genome-wide sequencing data interpretation

Maver Ales MD, Lovrecic Luca MD, PhD, Volk Marija MD, Rudolf Gorazd MD, MSc, Writzl Karin MD, PhD, Blatnik Ana MD, Hodzic Alenka PhD and Borut Peterlin MD, PhD

Genet Med advance online publication, March 31, 2016; doi:[10.1038/gim.2016.22](https://doi.org/10.1038/gim.2016.22)

In this article, the authors' first and last names were mistakenly switched. The correct author names are:

Ales Maver MD, Luca Lovrecic MD, PhD, Marija Volk MD, Gorazd Rudolf MD, MSc, Karin Writzl MD, PhD, Ana Blatnik MD, Alenka Hodzic PhD and Peterlin Borut MD, PhD

The authors regret the error.

ADDENDUM: Technical standards and guidelines for spinal muscular atrophy testing

Thomas W. Prior, PhD, Narasimhan Nagan, PhD, Elaine A. Sugarman, MS, CGC, Sat Dev Batish, PhD, and Corey Braastad, PhD

Genet Med (2011) DOI: [10.1097/GIM.0b013e318220d523](https://doi.org/10.1097/GIM.0b013e318220d523)

The ACMG Laboratory Quality Assurance Committee reaffirmed this guideline on March 9, 2016 with the following update to the Carrier Testing section on page 689: Recently, the presence of an extended haplotype block specific to *SMN1* duplications was reported in individuals of Ashkenazi Jewish and African American ethnicities¹. Testing for haplotype specific markers in conjunction with carrier testing offers an incremental improvement in residual risk estimates following a negative carrier test result.

¹Luo M, Liu L, Peter I, Zhu J, Scott SA, Zhao G, Eversley C, Kornreich R, Desnick RJ, and Edelman L. An Ashkenazi Jewish *SMN1* haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. *Genet Med* 2014;16:149-56.

This Addendum was approved by the Board of Directors of the American College of Medical Genetics and Genomics on April 25, 2016.